• LENSAR highlighted growth in recurring revenue, with 12-month trailing recurring revenue at USD 47.37 million, up 12.3%.
• Revenue for three months ended March 31, 2026 fell 5.2% to USD 13.4 million, while net income swung to USD 36.3 million from a loss of USD 27.3 million.
• Global installed base reached 440 systems in Q1 2026, up 69% since ALLY launch.
• US procedure share rose to 23.4% in Q1 2026, up 9.3 percentage points since ALLY launch.
• Presentation reiterated workflow claims for ALLY robotic cataract laser system, including staff time savings of up to 19 minutes per procedure and annual ASC savings of USD 405,000-USD 540,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LENSAR Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.